+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver Cancer Drug Market Size, Share & Trends Analysis Report by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Type (Hepatocellular Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region, and Segment Forecasts 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 5899559
Description Jump to:
The Liver Cancer Drug Market was valued at USD 3.67 billion in 2024, and is projected to reach USD 9.81 billion by 2030, rising at a CAGR of 17.90%. The market is projected to grow at a CAGR of 17.9% from 2025 to 2030. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights

  • The targeted therapy segment held the largest market revenue share of 53.1% in 2024 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
  • Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 38.2% revenue share in 2024. HCC Is the most common type of primary liver cancer.
  • Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.7% in 2024.
  • North America liver cancer drug market held a revenue share of 38.7% in 2024.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapy
1.2.2. Type
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Liver Cancer Drug Market: Therapy Business Analysis
4.1. Therapy Market Share, 2024 & 2030
4.2. Therapy Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
4.4. Targeted Therapy
4.4.1. Targeted Therapy Market, 2018-2030 (USD Million)
4.5. Immunotherapy
4.5.1. Immunotherapy Market, 2018-2030 (USD Million)
4.6. Chemotherapy
4.6.1. Chemotherapy Market, 2018-2030 (USD Million)
4.7. Others
4.7.1. Others Market, 2018-2030 (USD Million)
Chapter 5. Liver Cancer Drug Market: Type Business Analysis
5.1. Type Market Share, 2024 & 2030
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Hepatocellular Carcinoma
5.4.1. Hepatocellular Carcinoma Market, 2018-2030 (USD Million)
5.5. Cholangio Carcinoma
5.5.1. Cholangio Carcinoma Market, 2018-2030 (USD Million)
5.6. Hepatoblastoma
5.6.1. Hepatoblastoma Market, 2018-2030 (USD Million)
5.7. Others
5.7.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Liver Cancer Drug Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018-2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2018-2030 (USD Million)
Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Liver Cancer Drug Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Europe
7.5.1. Europe Liver Cancer Drug Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.3. UK
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. UK Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8. MEA
7.8.1. MEA Liver Cancer Drug Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Exelixis, Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Merck KGaA
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Eisai Co., Ltd.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Bristol-Myers Squibb Company
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Thermo Fisher Scientific Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Pfizer Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Eli Lilly and Company
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. F. Hoffmann-La Roche Ltd
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Novartis AG
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Bayer AG
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 Global Liver Cancer Drug Market, by Region, 2018-2030 (USD Million)
Table 4 Global Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 5 Global Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 6 Global Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 7 North America Liver Cancer Drug Market, by Country, 2018-2030 (USD Million)
Table 8 North America Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 9 North America Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 10 North America Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 11 U.S. Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 12 U.S. Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 13 U.S. Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 14 Canada Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 15 Canada Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 16 Canada Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 17 Mexico Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 18 Mexico Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 19 Mexico Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 20 Europe Liver Cancer Drug Market, by Country, 2018-2030 (USD Million)
Table 21 Europe Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 22 Europe Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 23 Europe Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 24 Germany Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 25 Germany Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 26 Germany Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 27 UK Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 28 UK Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 29 UK Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 30 France Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 31 France Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 32 France Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 33 Italy Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 34 Italy Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 35 Italy Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 36 Spain Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 37 Spain Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 38 Spain Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 39 Denmark Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 40 Denmark Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 41 Denmark Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 42 Sweden Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 43 Sweden Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 44 Sweden Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 45 Norway Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 46 Norway Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 47 Norway Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 48 Asia Pacific Liver Cancer Drug Market, by Country, 2018-2030 (USD Million)
Table 49 Asia Pacific Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 50 Asia Pacific Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 51 Asia Pacific Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 52 Japan Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 53 Japan Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 54 Japan Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 55 China Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 56 China Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 57 China Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 58 India Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 59 India Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 60 India Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 61 Australia Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 62 Australia Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 63 Australia Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 64 South Korea Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 65 South Korea Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 66 South Korea Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 67 Thailand Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 68 Thailand Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 69 Thailand Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 70 Latin America Liver Cancer Drug Market, by Country, 2018-2030 (USD Million)
Table 71 Latin America Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 72 Latin America Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 73 Latin America Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 74 Brazil Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 75 Brazil Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 76 Brazil Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 77 Argentina Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 78 Argentina Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 79 Argentina Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 80 Middle East & Africa Liver Cancer Drug Market, by Country, 2018-2030 (USD Million)
Table 81 Middle East & Africa Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 82 Middle East & Africa Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 83 Middle East & Africa Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 84 South Africa Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 85 South Africa Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 86 South Africa Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 87 Saudi Arabia Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 88 Saudi Arabia Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 89 Saudi Arabia Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 90 UAE Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 91 UAE Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 92 UAE Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
Table 93 Kuwait Liver Cancer Drug Market, by Therapy, 2018-2030 (USD Million)
Table 94 Kuwait Liver Cancer Drug Market, by Type, 2018-2030 (USD Million)
Table 95 Kuwait Liver Cancer Drug Market, by Distribution Channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Liver Cancer Drug Market Segmentation
Figure 2 Market Research Process
Figure 3 Data Triangulation Techniques
Figure 4 Primary Research Pattern
Figure 5 Market Research Approaches
Figure 6 Value-Chain-Based Sizing & Forecasting
Figure 7 Market Formulation & Validation
Figure 8 Market Snapshot
Figure 9 Therapy and Type Outlook (USD Million)
Figure 10 Distribution Channel Outlook (USD Million)
Figure 11 Competitive Landscape
Figure 12 Liver Cancer Drug Market Dynamics
Figure 13 Liver Cancer Drug Market: Porter’s Five Forces Analysis
Figure 14 Liver Cancer Drug Market: PESTLE Analysis
Figure 15 Liver Cancer Drug Market: Therapy Segment Dashboard
Figure 16 Liver Cancer Drug Market: Therapy Market Share Analysis, 2024 & 2030
Figure 17 Targeted Therapy Market, 2018-2030 (USD Million)
Figure 18 Immunotherapy Market, 2018-2030 (USD Million)
Figure 19 Chemotherapy Market, 2018-2030 (USD Million)
Figure 20 Others Market, 2018-2030 (USD Million)
Figure 21 Liver Cancer Drug Market: Type Segment Dashboard
Figure 22 Liver Cancer Drug Market: Type Market Share Analysis, 2024 & 2030
Figure 23 Hepatocellular Carcinoma Market, 2018-2030 (USD Million)
Figure 24 Cholangio Carcinoma Market, 2018-2030 (USD Million)
Figure 25 Hepatoblastoma Market, 2018-2030 (USD Million)
Figure 26 Others Market, 2018-2030 (USD Million)
Figure 27 Liver Cancer Drug Market: Distribution Channel Segment Dashboard
Figure 28 Liver Cancer Drug Market: Distribution Channel Market Share Analysis, 2024 & 2030
Figure 29 Hospital Pharmacies Market, 2018-2030 (USD Million)
Figure 30 Retail Pharmacies Market, 2018-2030 (USD Million)
Figure 31 Online Pharmacies Market, 2018-2030 (USD Million)
Figure 32 Liver Cancer Drug Market Revenue, by Region
Figure 33 Regional Marketplace: Key Takeaways
Figure 34 Regional Marketplace: Key Takeaways
Figure 35 North America Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 36 U.S. Country Dynamics
Figure 37 U.S. Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 38 Canada Country Dynamics
Figure 39 Canada Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 40 Mexico Country Dynamics
Figure 41 Mexico Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 42 Europe Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 43 Germany Country Dynamics
Figure 44 Germany Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 45 UK Country Dynamics
Figure 46 UK Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 47 France Country Dynamics
Figure 48 France Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 49 Italy Country Dynamics
Figure 50 Italy Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 51 Spain Country Dynamics
Figure 52 Spain Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 53 Norway Country Dynamics
Figure 54 Norway Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 55 Sweden Country Dynamics
Figure 56 Sweden Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 57 Denmark Country Dynamics
Figure 58 Denmark Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 59 Asia Pacific Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 60 Japan Country Dynamics
Figure 61 Japan Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 62 China Country Dynamics
Figure 63 China Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 64 India Country Dynamics
Figure 65 India Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 66 Australia Country Dynamics
Figure 67 Australia Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 68 South Korea Country Dynamics
Figure 69 South Korea Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 70 Thailand Country Dynamics
Figure 71 Thailand Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 72 Latin America Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 73 Brazil Country Dynamics
Figure 74 Brazil Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 75 Argentina Country Dynamics
Figure 76 Argentina Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 77 MEA Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 78 South Africa Country Dynamics
Figure 79 South Africa Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 80 Saudi Arabia Country Dynamics
Figure 81 Saudi Arabia Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 82 UAE Country Dynamics
Figure 83 UAE Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 84 Kuwait Country Dynamics
Figure 85 Kuwait Liver Cancer Drug Market, 2018-2030 (USD Million)
Figure 86 Company Categorization
Figure 87 Company Market Position Analysis
Figure 88 Strategic Framework

Companies Mentioned

The major companies profiled in this Liver Cancer Drug market report include:
  • Exelixis, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bayer AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.67 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.81 Billion
Compound Annual Growth Rate17.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Liver Cancer Drugs Market by Type, Distribution channel - Global Forecast 2025-2030 - Product Image

Liver Cancer Drugs Market by Type, Distribution channel - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Drugs - Global Strategic Business Report - Product Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • 277 Pages
  • Global
From
Cellular Immunotherapy Market by Type (CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy), Technology Type (Cytokines & Immunomodulators, Monoclonal Antibodies), Indication, Institution Category - Global Forecast 2025-2030 - Product Image

Cellular Immunotherapy Market by Type (CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy), Technology Type (Cytokines & Immunomodulators, Monoclonal Antibodies), Indication, Institution Category - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
T-Cell Immunotherapy Market by Therapy Type (CAR-T Therapy, TCR Therapy, TIL Therapy), Cell Source (Allogeneic Cells, Autologous Cells), Target Antigens, Manufacturing Method, Patient Type, Indication, End-User - Global Forecast 2025-2030 - Product Image

T-Cell Immunotherapy Market by Therapy Type (CAR-T Therapy, TCR Therapy, TIL Therapy), Cell Source (Allogeneic Cells, Autologous Cells), Target Antigens, Manufacturing Method, Patient Type, Indication, End-User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.